139 related articles for article (PubMed ID: 35637550)
1. Rovatirelin ameliorates motor dysfunction in the cytosine arabinoside-induced rat model of spinocerebellar degeneration via acetylcholine and dopamine neurotransmission.
Ijiro T; Yaguchi A; Yokoyama A; Kiguchi S
Clin Exp Pharmacol Physiol; 2022 Sep; 49(9):950-958. PubMed ID: 35637550
[TBL] [Abstract][Full Text] [Related]
2. Ameliorating effect of rovatirelin on the ataxia in rolling mouse Nagoya.
Ijiro T; Yaguchi A; Yokoyama A; Abe Y; Kiguchi S
Eur J Pharmacol; 2020 Sep; 882():173271. PubMed ID: 32534077
[TBL] [Abstract][Full Text] [Related]
3. Effect of rovatirelin, a novel thyrotropin-releasing hormone analog, on the central noradrenergic system.
Ijiro T; Nakamura K; Ogata M; Inada H; Kiguchi S; Maruyama K; Nabekura J; Kobayashi M; Ishibashi H
Eur J Pharmacol; 2015 Aug; 761():413-22. PubMed ID: 26142830
[TBL] [Abstract][Full Text] [Related]
4. Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials.
Nishizawa M; Onodera O; Hirakawa A; Shimizu Y; Yamada M;
J Neurol Neurosurg Psychiatry; 2020 Mar; 91(3):254-262. PubMed ID: 31937586
[TBL] [Abstract][Full Text] [Related]
5. Non-clinical pharmacokinetic profiles of rovatirelin, an orally available thyrotropin-releasing hormone analogue.
Kobayashi K; Abe Y; Harada H; Oota E; Endo T; Takeda H
Xenobiotica; 2019 Jan; 49(1):106-119. PubMed ID: 29300135
[TBL] [Abstract][Full Text] [Related]
6. Effect of YM-14673, a new thyrotropin releasing hormone analogue, on ataxic gait in cytosine arabinoside-treated mice.
Yamamoto M; Shimizu M
Eur J Pharmacol; 1989 Aug; 166(3):545-7. PubMed ID: 2509218
[TBL] [Abstract][Full Text] [Related]
7. [Studies on the behavioral pharmacology of TRH-T in cytosine arabinoside-induced ataxic mice: a comparison with genetically ataxic mice].
Matsui K; Mano Y; Mukoyama M; Muramoto O; Toyoshima E; Ando K
Jikken Dobutsu; 1983 Jan; 32(1):13-9. PubMed ID: 6406242
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of thyrotropin releasing hormone (TRH) on motor execution and motor adaptation process in patients with spinocerebellar degeneration.
Shimizu T; Tsutsumi R; Shimizu K; Tominaga N; Nagai M; Ugawa Y; Nishiyama K; Hanajima R
J Neurol Sci; 2020 Aug; 415():116927. PubMed ID: 32474221
[TBL] [Abstract][Full Text] [Related]
9. Effects of taltirelin hydrate (TA-0910), a novel thyrotropin-releasing hormone analog, on in vivo dopamine release and turnover in rat brain.
Fukuchi I; Asahi T; Kawashima K; Kawashima Y; Yamamura M; Matsuoka Y; Kinoshita K
Arzneimittelforschung; 1998 Apr; 48(4):353-9. PubMed ID: 9608876
[TBL] [Abstract][Full Text] [Related]
10. Taltirelin improves motor ataxia independently of monoamine levels in rolling mouse nagoya, a model of spinocerebellar atrophy.
Nakamura T; Honda M; Kimura S; Tanabe M; Oda S; Ono H
Biol Pharm Bull; 2005 Dec; 28(12):2244-7. PubMed ID: 16327158
[TBL] [Abstract][Full Text] [Related]
11. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.
Huang M; Li Z; Dai J; Shahid M; Wong EH; Meltzer HY
Neuropsychopharmacology; 2008 Nov; 33(12):2934-45. PubMed ID: 18418367
[TBL] [Abstract][Full Text] [Related]
12. TRH Analog, Taltirelin Improves Motor Function of Hemi-PD Rats Without Inducing Dyskinesia via Sustained Dopamine Stimulating Effect.
Zheng C; Chen G; Tan Y; Zeng W; Peng Q; Wang J; Cheng C; Yang X; Nie S; Xu Y; Zhang Z; Papa SM; Ye K; Cao X
Front Cell Neurosci; 2018; 12():417. PubMed ID: 30555300
[TBL] [Abstract][Full Text] [Related]
13. Taltirelin. Tanabe Seiyaku.
Brown W
IDrugs; 1999 Oct; 2(10):1059-68. PubMed ID: 16118715
[TBL] [Abstract][Full Text] [Related]
14. Lack of behavioral tolerance by repeated treatment with taltirelin hydrate, a thyrotropin-releasing hormone analog, in rats.
Asai H; Asahi T; Yamamura M; Yamauchi-Kohno R; Saito A
Pharmacol Biochem Behav; 2005 Dec; 82(4):646-51. PubMed ID: 16368129
[TBL] [Abstract][Full Text] [Related]
15. The long loop reflex in spinocerebellar degeneration and motor neuron disease--its changes with TRH therapy.
Touge T; Takeuchi H; Yamada A; Miki H; Nishioka M
Electromyogr Clin Neurophysiol; 1990; 30(3):131-40. PubMed ID: 2112456
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of in vivo anti-hypothermic effect of all stereoisomers of the thyrotropin-releasing hormone mimetic: Rovatirelin Hydrate.
Kobayashi N; Sato N; Sugita K; Takahashi K; Sugawara T; Tada Y; Yoshikawa T
J Pept Sci; 2019 Dec; 25(12):e3228. PubMed ID: 31713944
[TBL] [Abstract][Full Text] [Related]
17. Glycine transporter blockade ameliorates motor ataxia in a mouse model of spinocerebellar atrophy.
Tanabe M; Nakano T; Honda M; Ono H
J Pharmacol Sci; 2009 Mar; 109(3):444-8. PubMed ID: 19270429
[TBL] [Abstract][Full Text] [Related]
18. An acetylcholine-dopamine interaction in the nucleus accumbens and its involvement in ethanol's dopamine-releasing effect.
Loftén A; Adermark L; Ericson M; Söderpalm B
Addict Biol; 2021 May; 26(3):e12959. PubMed ID: 32789970
[TBL] [Abstract][Full Text] [Related]
19. Effect of intranasal administration of thyrotropin-releasing hormone on ataxic gait in staggerer mice.
Matsui K; Itoh K; Mizumachi M; Kubo H; Goto T; Sato S; Wada K
Neurosci Lett; 1996 Jul; 212(2):115-8. PubMed ID: 8832652
[TBL] [Abstract][Full Text] [Related]
20. [Synthesis and pharmacological action of TRH analog peptide (Taltirelin)].
Yamamura M; Suzuki M; Matsumoto K
Nihon Yakurigaku Zasshi; 1997 Oct; 110 Suppl 1():33P-38P. PubMed ID: 9503402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
